Get started
Author

Dandan Li

Targeted delivery of Saikosaponin A and doxorubicin via hyaluronic acid-modified ZIF-8 nanoparticles for TNBC treatment: Inhibiting metastasis and reducing cardiotoxicity
2024 · Dandan Li, Yu Yao, et al. · Biomaterials Advances · 24
A Selective FGFR1/2 PROTAC Degrader with Antitumor Activity
2024 · Ying Kong, Xinyue Zhao, et al. · Molecular Cancer Therapeutics · 11
Enhancing breast cancer treatment: mesoporous dopamine nanoparticles in synergy with chrysin for photothermal therapy
2024 · Jing Zhu, Heng Zhang, et al. · Frontiers in Oncology · 9
[Clinical and immunohistopathologic study of phosphaturic mesenchymal tumor].
2018 · D M Li, H W Wu, et al. · PubMed · 7
Shoutai pill promotes endometrial decidualization and prevents recurrent spontaneous abortion through dual regulation of apoptosis and ECM remodeling by the LDHA-lactate axis
2025 · Ruigan Shi, Min Jiang, et al. · Journal of Ethnopharmacology · 4
A network pharmacology analysis of curcumin in the treatment of oral submucous fibrosis
2025 · Fangping Deng, Shuxin Fu, et al. · Computational Biology and Chemistry · 2
[Consistency analysis of immunohistochemistry staining for different PD-L1 antibodies in the cancer cells of non-small cell lung cancer].
2020 · M Li, L Y Chen, et al. · PubMed · 1
Figure S5 from A Selective FGFR1/2 PROTAC Degrader with Antitumor Activity
2026 · Ying Kong, Xinyue Zhao, et al.
Figure S3 from A Selective FGFR1/2 PROTAC Degrader with Antitumor Activity
2026 · Ying Kong, Xinyue Zhao, et al.
Figure S2 from A Selective FGFR1/2 PROTAC Degrader with Antitumor Activity
2026 · Ying Kong, Xinyue Zhao, et al.
Figure S7 from A Selective FGFR1/2 PROTAC Degrader with Antitumor Activity
2026 · Ying Kong, Xinyue Zhao, et al.
Table S4 from A Selective FGFR1/2 PROTAC Degrader with Antitumor Activity
2026 · Ying Kong, Xinyue Zhao, et al.
Figure S1 from A Selective FGFR1/2 PROTAC Degrader with Antitumor Activity
2026 · Ying Kong, Xinyue Zhao, et al.
Figure S4 from A Selective FGFR1/2 PROTAC Degrader with Antitumor Activity
2026 · Ying Kong, Xinyue Zhao, et al.
Table S3 from A Selective FGFR1/2 PROTAC Degrader with Antitumor Activity
2026 · Ying Kong, Xinyue Zhao, et al.
Table S2 from A Selective FGFR1/2 PROTAC Degrader with Antitumor Activity
2026 · Ying Kong, Xinyue Zhao, et al.
Figure S6 from A Selective FGFR1/2 PROTAC Degrader with Antitumor Activity
2026 · Ying Kong, Xinyue Zhao, et al.
Table S1 from A Selective FGFR1/2 PROTAC Degrader with Antitumor Activity
2026 · Ying Kong, Xinyue Zhao, et al.
Table S5 from A Selective FGFR1/2 PROTAC Degrader with Antitumor Activity
2026 · Ying Kong, Xinyue Zhao, et al.
A radiotherapeutic paradox: ellagic acid sensitizes tumors while attenuating radiation-induced myocardial injury
2026 · Dandan Li, Siqin Xie, et al. · Frontiers in Oncology
PDF
Research progress on the Sonic Hedgehog signaling pathway in the central nervous system: Novel insights
2025 · Nuokun Li, Shiyi Wen, et al. · Neural Regeneration Research
[Curcumin inhibits lipid metabolism in non-small cell lung cancer by downregulating the HIF-1α pathway].
2025 · Dandan Li, Jiaxin Chu, et al. · Europe PMC (PubMed Central)
Visualization of endogenous p27 and Ki67 reveals the importance of a c-Myc-driven metabolic switch in promoting survival of quiescent cancer cells: Erratum
2024 · Ting La, Song Chen, et al. · Theranostics
PDF
Supplementary Figure legend from A Selective FGFR1/2 PROTAC Degrader with Antitumor Activity
2024 · Ying Kong, Xinyue Zhao, et al.
Table S2 from A Selective FGFR1/2 PROTAC Degrader with Antitumor Activity
2024 · Ying Kong, Xinyue Zhao, et al.
Works count: 48
Citation count: 58
H-index: 4
I10-index: 2
Year
Topic
Type